Novo Nordisk CEO Lars Fruergaard Jørgensen will step down amid market challenges and a clinical disappointment for CagriSema.

Leo Pharma is doing an extensive revamp of its leadership team as it splits product strategy and international operations ...

It's been 13 weeks since Aardvark Therapeutics' $94 million initial public offering on Feb. 13 in the bleakest streak for ...

RFK Jr. advisor Calley Means challenges drugmakers considering pulling their investment in the US over Trump's most favored ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

Vinay Prasad may have just started as the new director of the FDA's biologics center, but he's 'planning to unleash a massive ...

Bristol Myers Squibb CEO Chris Boerner said America’s role as the global biopharma leader is at a 'pivot point' as the Trump ...

AGC Bio partners with Quell for vectors; Thermo Fisher makes Cybin's CYB003; PeptiSystems teams with Asahi Kasei; TriLink & ...

Jiangsu Hengrui seeks $1.2B Hong Kong IPO, with 75% for R&D. Chinese drugmaker has deals with Merck, Kailera, Ideaya & ties ...

HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare ...